{{Rsnum
|rsid=10885122
|Chromosome=10
|position=113042093
|Orientation=plus
|GMAF=0.2649
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 80.0 | 20.0 | 0.0
| HCB | 84.4 | 15.6 | 0.0
| JPT | 85.4 | 14.6 | 0.0
| YRI | 7.9 | 27.0 | 65.1
| ASW | 0.0 | 0.0 | 0.0
| CHB | 84.4 | 15.6 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=20081858
|Trait=Fasting glucose-related traits
|Title=New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
|RiskAllele=G
|Pval=0.000002
|OR=None
|ORtxt=None
|OA=1
}}

{{PharmGKB
|RSID=rs10885122
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:20081858
|Annotation=Phenotype : In a meta-analysis of 21 GWAS cohorts followed by analysis in additional individuals, this SNP was found to be associated with fasting glucose level. Study size: 118,410. Significance metric(s): p = 2.9 x 10(-16). Study population/ethnicity: Non-diabetic Individuals of European descent. Type of association: CO;GN.
|Drugs=
|Drug Classes=
|Diseases=Diabetes Mellitus, Type 2
|Curation Level=Curated
|PharmGKB Accession ID=PA165281940
}}

{{PMID Auto
|PMID=21887289
|Title=Glucose-Raising Genetic Variants in MADD and ADCY5 Impair Conversion of Proinsulin to Insulin
|OA=1
}}

{{PMID Auto
|PMID=20870969
|Title=Genetic predisposition to long-term nondiabetic deteriorations in glucose homeostasis: Ten-year follow-up of the GLACIER study.
|OA=1
}}

{{PMID Auto
|PMID=21455730
|Title=Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies.
|OA=1
}}

{{PMID Auto GWAS
|PMID=22581228
|Trait=None
|Title=A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.
|RiskAllele=
|Pval=9E-8
|OR=None
|ORtxt=None
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10885122
|overall_frequency_n=79
|overall_frequency_d=128
|overall_frequency=0.617188
|n_genomes=41
|n_genomes_annotated=0
|n_haplomes=67
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=22698489
|Title=Nonfasting glucose, ischemic heart disease, and myocardial infarction: a Mendelian randomization study.
}}

{{PMID Auto
|PMID=23466530
|Title=SCN1AIVS5-91G>A polymorphism is associated with susceptibility to epilepsy but not with drug responsiveness.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}